[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Walter Reed Army Institute of Research (WRAIR)\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":123},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,73,97],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100641647","the-efficacy-of-vitamin-d-supplementation-to-sustain-performance-outcomes-100641647",false,"NCT07654777","The Efficacy of Vitamin D Supplementation to Sustain Performance Outcomes","Assessment of the Efficacy of Vitamin D Supplementation to Sustain Performance of Military-Relevant Laboratory Tasks Under Acutely Stressed Conditions: A Randomized, Double-Blind, Placebo-Controlled Study","Inclusion Criteria:\n\n* Male and non-pregnant, non-lactating females 18 to 40 (inclusive) years of age.\n* Females of child-bearing potential must be using some form of birth control, if sexually active (e.g., oral contraceptive, condom, intrauterine device, etc.)\n* Score of 80% or greater on a \"Volunteer Comprehension Assessment\" test. A maximum of two attempts is permitted.\n* Blood 25 hydroxy vitamin D \\[25(OH)D\\] levels at the Screening visit of 30 nmol\u002FL (12 ng\u002FmL) (inclusive) - \\\u003C 75 nmol\u002FL (30 ng\u002FmL).\n\nExclusion Criteria:\n\n* Contraindications due to vitamin D supplementation, including a history of hypercalcemia, malabsorption syndrome, hypervitaminosis D, or allergic\u002Fhypersensitivity reactions to vitamin D or a history of other adverse reactions to vitamin D supplementation.\n* Taking a vitamin D3 or D2 supplement or a supplement containing vitamin D3 or D2 (excluding vitamin D-fortified foods) during the participation. Volunteers who take vitamin D3 or D2 supplement before their participation can be eligible if they agree to stop taking the supplement(s) starting 1 month prior to the enrollment\u002Fbaseline visit until the end of the post-supplementation visit. Blood 25(OH)D levels of the volunteers who stopped taking the supplements after the screening visit will be tested before the Enrollment\u002FBaseline visit to ensure their 25(OH)D fall within the inclusionary ranges. Volunteers who are not able to stop taking vitamin D supplements or supplements containing vitamin D due to medical\u002Fhealth or any other reasons (especially if the volunteer is taking supplements containing vitamin D under the direction of a healthcare provider) are not eligible.\n* Not being able to tolerate electric shocks delivered through the stress belt.\n* Self-reported propensity for adverse skin reactions, such as excessive irritation, burning, itching, hives, and redness, in response to physical or heat stimuli.\n* A history of abuse or addiction to recreational or illicit drugs (including marijuana and alcohol) or prescribed medications (e.g., opioids) (diagnosed or suspected based on the medical history).\n* Use a nicotine product (e.g., cigarette, cigar, vape) more than 3 days per week or not be able to go without using these products during any lab visits.\n* Self-reported caffeine use in excess of 600 mg (e.g., approximately 10 caffeinated sodas or approximately 29 ounces of brewed coffee) per day on average or not being able to go without caffeine during the in-lab visits.\n* History of neurologic disorder (to include but not limited to epilepsy, hydrocephalus, multiple sclerosis). An infrequent or resolved single neurological event (e.g., childhood seizure, rare sporadic migraine headaches, resolved meningeal infection with no sequelae) or a history of mild traumatic brain injury may be deemed non-exclusionary at the discretion of the examining study medical investigator.\n* Score of 10 or above on the Beck Depression Inventory (BDI) or a score of \\> 0 on item 9 \"Suicidal Thoughts or Wishes\" of the BDI.\n* Score of 33 or above on the Posttraumatic Stress Disorder (PTSD) Checklist, 5th Edition.\n* Score 20 or above on the Patient-Reported Outcomes Measurement Information System (PROMIS) Emotional Distress-Anxiety-7-Item Short form.\n* History of cardiovascular disease (to include but not limited to arrhythmias, valvular heart disease, congestive heart failure, history of sudden cardiac death or myocardial infarction).\n* Asthma, any type of reactive airways disease, or any pulmonary disease requiring daily inhaler use.\n* Regularly work night shifts or have a habitual sleep\u002Fwake schedule that is not conducive for the optimal performance on cognitive, physical, and\u002For emotional tasks during the study visits (e.g., extremely early or late habitual bedtime or rise time; to be determined on a case-by-case basis by the principal investigator or an associate investigator).\n* A diagnosis of sleep apnea.\n* Kidney disease or kidney abnormalities, liver disease or liver abnormalities, or any other metabolic derangements (endocrine disorders, hyperglycemia, etc.) that could alter neurophysiological function.\n* History of kidney stones.\n* Osteoporosis or low bone density.\n* Self-reported history of hospitalization for a psychiatric disorder within the past year or with a previous history of a psychotic, bipolar disorder or personality disorder. For a history of a diagnosis of any other psychiatric disorder, the potential participant's symptoms must either be resolved to a degree that a diagnosis is no longer applied or their symptoms must have been stabilized by pharmacological or nonpharmacological treatments for a period of at least 90 days or greater as deemed exclusionary or non-exclusionary at the discretion of the examining study medical investigator.\n* Self-reported or suspected current use of antipsychotics, anticonvulsants, or mood stabilizers, to be determined on a case-by-case basis by the examining study medical investigator.\n* Self-reported or suspected current use of products or drugs that have central nervous system depressant effects, to be determined on a case-by-case basis by the examining study medical investigator.\n* Self-reported or suspected use of products or drugs that are contraindicated to the study supplement or significantly affect the participant's study performance and that cannot be safely discontinued during the study participation. To be determined on a case-by-case basis by the examining study medical investigator.\n* Self-reported or suspected current heavy alcohol use (minimum limit to define heavy alcohol use is 14 drinks per week for males and 7 drinks per week for females or as determined by the examining study medical investigator).\n* (Females only) Positive urine pregnancy test result.\n* (Females only) Self-reported or suspected current breast-feeding or collecting breast-milk.\n* Resting blood pressure above 140\u002F90 or resting pulse \\> 110 beats per minute.\n* Body Mass Index (BMI) ≥ 31. The inclusion of individuals with BMI between 30 and 31 (Obese Class I) will be determined using medical investigator's discretion.\n* Clinically significant values (as determined by the reviewing study medical investigator) for any hematology or chemistry parameter.\n* Positive urine drug result at any study visits. If tetrahydrocannabinol is positive at the screening visit and the volunteer wishes to have the second drug test, the volunteer will be allowed to have one additional urine drug test after a 1 to 5-month waiting period.\n* Positive saliva alcohol result at any study visits.\n* Inability to read (i.e., failing in the Volunteer Comprehension Assessment twice) and sign consent.\n* Failure to obtain required approved official leave to participate (federal civilian employees and active-duty military only).\n* Failure to cooperate with requirements of the study.\n* Self-reported or suspected current use of illicit drugs (including but not limited to benzodiazepines, amphetamines, and cocaine). In case of marijuana\u002Ftetrahydrocannabinol product use, the frequency up to twice a month will not be excluded. Current use of any other drugs at any frequency is excluded.\n* Current use and\u002For prescription for any medication the medical investigator determines would interact adversely with vitamin D supplementation, including but not limited to: orlistat, statins, corticosteroid medications, and thiazide diuretics.\n* Current diabetes.\n* Gastrointestinal disorders - motility disorders that might affect vitamin D absorption.\n* Failure to provide a social security number or tax identification number in order to be paid for screening and participation in the study.\n* Current participation in another ongoing clinical trial.\n* Prior participation in this study.",true,"ALL","18 Years","40 Years",{"count":21,"type":22},52,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to find out if vitamin D supplements help healthy adults maintain their cognitive and simple physical task performance and emotional state during highly stressful situations.\n\nThe main question it aims to answer is:\n\n\\- Does vitamin D help maintain cognitive and physical task performance and emotional state during highly stressful situations?\n\nResearchers will compare vitamin D to placebo (a look-alike tablet that contains no active ingredients) to see if vitamin D better maintain cognitive and physical task performance and emotional state during highly stressful situations.\n\nParticipants will:\n\n* Take vitamin D or placebo tablets daily for 8 weeks.\n* Perform cognitive and simple physical tasks and rate their emotional state under highly stressful situations.\n* Wear a stress belt that delivers mild electric shocks 1 - 5 times while participants are performing laboratory tasks.\n* Wear a wristwatch-shaped activity monitor for 9 weeks.\n* Visit the laboratory 5 times.",[28],"Acute Stress Reaction",[30,31,32,33,34],"acute stress reaction","vitamin D","electrical shocks","neuropsychological tests","randomized controlled trial","RECRUITING","2026-06-15",{"date":38,"type":39},"2026-06-17","ACTUAL",{"date":41,"type":22},"2026-06",{"date":43,"type":22},"2027-09",{"name":45,"class":46},"Walter Reed Army Institute of Research (WRAIR)","FED",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":47},"100591573","phase-4-the-effects-of-propranolol-and-hydrocortisone-on-military-relevant-performance-outcomes-100591573","NCT06982183","The Effects of Propranolol and Hydrocortisone on Military-Relevant Performance Outcomes","The Effects of Propranolol and Hydrocortisone on Military-Relevant Performance Outcomes: A Randomized, Blinded, Placebo Controlled Study","Inclusion Criteria:\n\n* Male and non-pregnant, non-lactating females 18 to 40 (inclusive) years of age.\n* Females of child-bearing potential must be on some form of birth control, if sexually active (e.g., oral contraceptive, condom, intrauterine device, etc.)\n* Score of 80% or greater on a \"Volunteer Comprehension Assessment\" test.\n* Score equal to or greater than 54 on the Fear of Spiders Questionnaire.\n* Body weight between 91 and 250 pounds (inclusive).\n* Live close enough to be able to commute to Walter Reed Army Institute of Research during the study participation.\n\nExclusion Criteria:\n\n* Contraindications due to study medications, including a history of allergic\u002Fhypersensitivity reactions to a beta blocker or a steroid, or a history of other adverse reactions to these classes of drugs (such as an episode of steroid psychosis).\n* A history of allergic reactions to a spider bite.\n* A history of abuse or addiction to illicit drugs (including marijuana) or prescribed medication (e.g., opioid) (diagnosed or suspected based on the medical history).\n* Use a nicotine product (e.g., cigarette, cigar, vape) more than 3 days per week.\n* Self-reported caffeine use in excess of 600 mg (e.g., approximately 10 caffeinated sodas or approximately 29 ounces of brewed coffee) per day on average or not being able to go without caffeine during the In-Lab visits.\n* History of neurologic disorder (to include but not limited to epilepsy, hydrocephalus, MS). An infrequent or resolved single neurological event (e.g., childhood seizure, rare sporadic migraine headaches, resolved meningeal infection with no sequelae) or a history of mild traumatic brain injury may be deemed non-exclusionary at the discretion of the examining study medical investigator\n* Score of 10 or above on the Beck Depression Inventory (BDI) or a score of \\> 0 on item 9 \"Suicidal Thoughts or Wishes\" of the BDI\n* Score of 41 or above on the State-Trait Anxiety Inventory - Trait (STAI-T).\n* Score of 20 or above on the PROMIS Emotional Distress - Anxiety - Short Form.\n* Score of 33 or above on the PTSD Checklist, 5th Edition (PCL-5)\n* History of cardiovascular disease (to include but not limited to arrhythmias, valvular heart disease, congestive heart failure, history of sudden cardiac death or myocardial infarction).\n* A history of asthma or any type of reactive airways disease or any acute or chronic pulmonary disorder that could lead to a compromise of blood oxygenation in the setting of a modest reduction in tidal volume or respiratory rate, to include neuromuscular disorders.\n* Regularly work night shifts or have a habitual sleep\u002Fwake schedule that is not conducive to compliance with the recommended sleep time (11:00 pm - 6:00 am) during participation (e.g., extremely early or late habitual bedtime or rise time, to be determined on a case-by-case basis by the principal investigator or an associate investigator).\n* A diagnosis of sleep apnea.\n* Kidney disease or kidney abnormalities, liver disease or liver abnormalities, or any other metabolic derangements (endocrine disorders, hyperglycemia, etc.) that could alter neurophysiological function.\n* Liver disease or significant liver abnormalities as determined by examining study medical investigator.\n* Self-reported history of hospitalization for a psychiatric disorder within the past year or with a previous history of a psychotic, bipolar disorder or personality disorder. For a history of a diagnosis of any other psychiatric disorder, a potential participant's symptoms must either be resolved to a degree that a diagnosis is no longer applied or their symptoms must have been stabilized by pharmacological or nonpharmacological treatments for a period of at least 90 days or greater as deemed exclusionary or non-exclusionary at the discretion of the examining study medical investigator.\n* Self-reported or suspected current use of antipsychotics, anticonvulsants, or mood stabilizers, to be determined on a case-by-case basis by the examining study medical investigator.\n* Self-reported or suspected current use of products or drugs that have CNS depressant effects, to be determined on a case-by-case basis by the examining study medical investigator.\n* Self-reported or suspected use of products or drugs that cannot be safely discontinued during in-laboratory phases, to be determined on a case-by-case basis by the examining study medical investigator.\n* Self-reported or suspected current heavy alcohol use (minimum limit to define heavy alcohol use is 14 drinks per week for males and 7 drinks per week for females or as determined by the examining study medical investigator).\n* (Females only) Positive urine pregnancy result\n* (Females only) Self-reported or suspected current breast-feeding or collecting breast-milk.\n* Resting blood pressure above 140\u002F90 or resting pulse \\> 110 beats per minute. Note that if a repeat measurement is within range, the volunteer will not be excluded.\n* Resting blood pressure below 100\u002F60 or pulse oxygenation \\\u003C92%. Volunteers with a resting pulse \\\u003C 60 bpm will be excluded unless a history of regular vigorous aerobic exercise and findings on the physical examination (including BMI) suggest a high level of cardiovascular fitness, in which case a resting pulse in the range of 50 - 59 bpm may not be exclusionary.\n* BMI ≥ 31. The inclusion of individuals with BMI between 30 and 31 (Obese Class I) will be determined using medical investigator's discretion.\n* Clinically significant values (as determined by the reviewing study medical investigator) for any hematology or chemistry parameter. Reviewing study medical investigator may opt to repeat any clinically significant tests and include volunteers whose repeat test values are not clinically significant.\n* Currently on or recently ended immunotherapy (e.g., allergy shots).\n* Have taken a vaccine within 30 days prior to enrollment to the study. For volunteers who report recently taking a vaccine during the screening visit, their In-Lab Day 1 visit will be scheduled at least 30 days after the date of the most recent vaccination.\n* Positive urine drug result during screening visit or In-Lab Days 1- 2; Exhibiting behaviors consistent with illicit drug use on In-Lab Day 3.\n* Positive saliva alcohol result during screening visit or In-Lab Days 1-3.\n* Inability to read and sign consent.\n* Failure to obtain required approved official leave to participate (federal civilian employees and active duty military only)\n* Failure to cooperate with requirements of the study\n* Failure to provide viable emergency contact(s) for the duration of the study\n* Self-reported or suspected current use of illicit drugs (including but not limited to benzodiazepines, amphetamines, cocaine, marijuana).\n* Current use and\u002For prescription for opioid, steroid or anti-hypertensive and\u002For any medication the Medical Investigator deems would interact adversely with study compounds.\n* Current use of medications that can adversely interact with propranolol, hydrocortisone and\u002For morphine to include anti-depressants that are cytochrome P450 2D6 inhibitors.\n* Current diabetes.\n* GI disorders - motility disorders\n* Failure to pass certain tests\n* Failure to provide a social security number or tax identification number in order to be paid for screening and participation in the study.\n* Current participation in another ongoing clinical trial",{"count":56,"type":22},88,[58],"PHASE4","This clinical trial aims to evaluate the nature and duration of effects of three FDA-approved medications (propranolol and hydrocortisone) on military-relevant cognitive, emotional, and motor performance following an exposure to a stressful situation (i.e., exposure to a tarantula) in physically healthy adult volunteers (aged 18 - 40) with fear of spiders to help the future development of medications for treating Acute Stress Reactions.\n\nThe main questions this study aims to answer are:\n\nWill placebo treatment (oral placebo) result in significant decrements in Psychomotor Vigilance Task (PVT) performance compared to propranolol treatment?\n\nWill placebo treatment \\[intramuscular (IM) placebo\\] result in significant decrements in PVT performance compared to hydrocortisone treatment?\n\nParticipants will receive one of five study medications (oral propranolol, oral placebo, IM hydrocortisone, or IM placebo) after a brief exposure to a tarantula. Participants will complete cognitive and simple motor tasks and psychological assessments before and after the study medication administration.",[61,28],"Fear of Spiders",[61,63,64,34,33,30],"propranolol","hydrocortisone","2026-05-08",{"date":67,"type":39},"2026-05-13",{"date":69,"type":39},"2025-05-27",{"date":71,"type":22},"2026-09",{"name":45,"class":46},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":47},"100633934","tafenoquine-combinations-for-improved-radical-cure-efficacy-of-plasmodium-vivax-100633934","NCT07533136","Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium Vivax","Evaluating Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium Vivax","Inclusion Criteria:\n\n* Participants who meet all of the following criteria may participate in the study:\n\n  * Thai or non-Thai, male or non-pregnant\u002Fnon-lactating female, aged at least 18 years\n  * Willingness to participate in the study and provides signed written informed consent form\n  * Have P. vivax malaria mono-infection as determined by blood smear, with a parasitemia range of 100-400,000 parasites\u002Fmicroliter\n  * Have normal (non-deficient or \\>70% activity) G6PD phenotype as measured by quantitative spectrophotometry\n  * Agree to not seek outside medical care prior to contacting the WRAIR-AFRIMS study team if a fever develops during study participation (approximately 180 days), unless emergency medical care is required\n\nExclusion Criteria:\n\n* Participants meeting any of the following criteria will be excluded from this study:\n\n  * Have an allergic reaction to any of the study drugs or components (AL,TQ, artemisinins, PPQ or CQ)\n  * History of anti-malarial drug use within the past 14 days (28 days for mefloquine or PPQ)\n  * On screening EKG, found to have a QTcF of greater than 450 milliseconds (ms) (470 ms for females)\n  * History of sudden cardiac death in an immediate family member, or personal history of known symptomatic coronary artery disease or arrhythmias\n  * Acute or chronic, clinically significant, pulmonary, cardiovascular, hepatic, neurologic, or renal functional abnormality, as determined by history, physical examination, and laboratory evaluation; specific tests for this criteria, and in the definition of severe malaria, include:\n\n    * Hemoglobin level of \\\u003C7 g\u002FdL\n    * Alanine aminotransferase (ALT\u002FSGPT) and\u002For Aspartate transaminase (AST\u002FSGOT) more than two times upper limit of normal or total bilirubin greater than 3 mg\u002FdL\n    * Serum creatinine greater than 3 mg\u002FdL\n  * History of or current psychotic disorders (schizophrenia or other type of psychosis with hallucinations\u002Fdelusions)\n  * Have symptoms of severe malaria needing urgent treatment, such as impaired consciousness, shock, seizures, respiratory distress, unable to eat or drink, prostration (WHO guidelines for malaria, 2024) or other signs\u002Fsymptoms of concern to the doctors\n  * Are a pregnant or lactating female, or female of childbearing age, up to 50 years of age or otherwise individually assessed for childbearing potential, who does not agree to use an acceptable form of contraception (e.g. pills or injectable) during this study and for 1 month after study completion\n  * Chronic use of medications that may cause drug interactions with tafenoquine (metformin) and\u002For drugs known to prolong the QTc interval.\n  * Any other significant finding that in the opinion of the study physician would increase the risk of having an adverse outcome from participating in this study",{"count":81,"type":22},300,[25],"This study is to conduct a clinical trial of tafenoquine combinations to compare the rates of therapeutic efficacy of dihydroartemisinin-piperaquine or artemether-lumefantrine with tafenoquine to chloroquine plus tafenoquine in preventing recurrence of Plasmodium vivax over a 6-month period in adult subjects with uncomplicated P. vivax infection living in Thailand.",[85],"Uncomplicated P. Vivax Mono-infection",[87],"Plasmodium vivax, Tafenoquine, Artemisinin combination therapy","NOT_YET_RECRUITING","2026-04-09",{"date":91,"type":39},"2026-04-16",{"date":93,"type":22},"2026-05-01",{"date":95,"type":22},"2029-05-30",{"name":45,"class":46},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":23,"phases":107,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":47},"100463037","acoustic-stimulation-during-restricted-sleep-after-sleep-deprivation-100463037","NCT05309473","Acoustic Stimulation During Restricted Sleep After Sleep Deprivation","Slow-wave Sleep Enhancement Using Acoustic Stimulation to Facilitate Performance Recovery During Restricted Sleep After Sleep Deprivation","Inclusion Criteria:\n\n* Healthy men and non-pregnant, non-lactating women 18 to 39 years of age (inclusive)\n* Must demonstrate adequate comprehension of the protocol, by achieving a score of at least 80% correct on a short multiple-choice quiz. Individuals who fail to achieve a passing score on the initial quiz will be given one opportunity to retest after a review of protocol information. Individuals who fail the comprehension assessment for the second time will be disqualified.\n\nExclusion Criteria:\n\n* You must have learned English as your first language\n* You must have a body mass index (BMI) below 30 (this is a mathematical calculation of your height and weight)\n* You must not have current or a history of sleeping problems (for example, insomnia or sleep apnea), or symptoms that indicate a potential sleep disorder\n* You must get an average of 6-9 hours of sleep per night and maintain a normal sleep\u002Fwake schedule\n* You must not drink excessive amounts of caffeine, alcohol, or smoke cigarettes regularly\n* You must not be on certain medications (determined on a case by case basis)\n* You must test negative for illicit drugs\n* Women must not be pregnant or nursing\n* You must not be participating in another ongoing clinical trial\n* You must have a social security number or tax identification number in order to be paid for screening and participation in the study\n* You cannot have a history of the following conditions: Cardiovascular disease, a neurologic disorder, pulmonary disease requiring inhaler use, kidney disease or kidney abnormalities, liver disease of liver abnormalities, a history of psychiatric disorder requiring hospitalization or medication within the last two years or for a continuous period of more than 6 months in the last ten years","39 Years",{"count":106,"type":22},44,[25],"The purpose of this study is to determine if brief sounds or tones presented within a restricted period of recovery sleep after a period of sleep deprivation will enhance restorative properties and improve performance during a subsequent period of wakefulness.",[110,111,112,113,114],"Sleep Deprivation","Sleep Restriction","Acoustic Stimulation","Performance","Alertness","2024-04-22",{"date":117,"type":39},"2024-04-23",{"date":119,"type":39},"2022-03-14",{"date":121,"type":22},"2026-10",{"name":45,"class":46},""]